Kornimate/medical-research-clean huggingface dataset:
prevalence of asthma and allergies among children in uae

Conditions: Asthma

Summary: multicenter, cross-sectional study to recruit a random sample of 6000 children via school class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.

multicenter, cross-sectional study to recruit a random sample of 6000 children via school class registers: 3000 children aged 13-14 years and 3000 children aged 6-7 years.standard isaac core questions for wheezing, rhinitis, and atopic dermatitis will be used. the isaac questionnaire has been validated by the world health organization and translated into many languages, and used in many countries. in this study, the arabic and english version will be used. in addition, questions regarding exposure to arabian incense "bokhor" and smoking questions of the environmental questionnaire will be included. isaac questionnaires 1. core questionnaire on wheezing. 2. core questionnaire on rhinitis. 3. core questionnaire on atopic dermatitis. 4. smoking questions of the environmental questionnaire. 5. video questionnaire on wheezing (only for 13-14 years age group, if applicable)

Eligibility criteria:
inclusion criteria: * children with age 6 to 7 years or with age 13 to 14 years at the time of questionnaires completion, and residing in dubai and the northern emirates of uae. * children aged 6 to 7 years or 13 to14 years, whose legal guardians give their consent. * able to give assent in the 13 to 14 years group. * able to comprehend and answer the questionnaire themselves in the 13 to 14 years group. exclusion criteria: * aged 13 to 14 years and unable to answer the questionnaire due to physical or mental disability. * parent or legal guardian refuses sign and return consent for the 6 to 7 years group and the 13 to 14 years group.
diclofenac patch for treatment of acute pain due to mild to moderate ankle sprain

Conditions: Acute Pain; Ankle Sprain

Summary: the primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium topical patch in reducing acute pain due to mild to moderate ankle sprains when applied to the painful area.

this randomized, double-blind, placebo-controlled, parallel group study will be conducted in patients with mild or moderate ankle sprains. eligible patients will be randomized (in a 1:1 ratio) to receive double-blind treatment with either the diclofenac topical patch or a matching placebo patch to be applied once daily for 7 days. patients will return to the clinic for assessments on day 3 and day 7; a follow-up assessment will be conducted on day 14. patients will complete an electronic diary in which assessments including pain intensity, pain relief and functional disability will be recorded twice daily. ratings of the quality of sleep will be recorded in the diary each morning, and the use of study treatment and rescue medication will be recorded in the diary each day.

Eligibility criteria:
inclusion criteria: * male and female subjects 17 - 75 years of age * sustained recent, painful unilateral mild to moderate ankle sprain * meet baseline pain criterion exclusion criteria: * open wound or infection at site of injury * evidence of severe injury or ankle fracture * use of oral nsaids or opioids within 12 - 24 hours of injury * presence or history of peptic ulcers or gi bleeding * a history of intolerance to nsaids, acetaminophen, adhesives * positive pregnancy test * positive drug screen

Keywords: diclofenac ankle sprain acute pain topical patch acute pain due to mild to moderate ankle sprain
a phase 1, two-part, randomized study to evaluate the pharmacokinetics, safety, and tolerability of a liquid formulation of tricaprilin and matching placebo in healthy subjects

Conditions: Alzheimer Disease

Summary: the purpose of this study is to evaluate the pk, safety, and tolerability of a new liquid formulation of tricaprilin.


Eligibility criteria:
main inclusion criteria: * healthy males and non-pregnant, non-lactating healthy females aged 18 to 55 years inclusive at time of signing informed consent with a body weight ≥55 kg. * body mass index (bmi) 18.0 to 32.0 kg/m2 as measured at screening or, if outside the range, considered not clinically significant by the investigator. main exclusion criteria: * serious adverse reaction or serious hypersensitivity to any drug or formulation excipients * subjects with a history of fainting, dizziness, bradycardia or hypotension as considered clinically significant by the investigator * subject has a medical condition that may adversely affect taste or smell activity
study to evaluate the efficacy and safety of dwp14012 in patients with non erosive reflux disease

Conditions: Non-Erosive Gastroesophageal Reflux Disease

Summary: the purpose of this study is to demonstrate the superiority of efficacy of dwp14012, once daily (qd), compared to placebo in patients with non-erosive reflux disease at week 4.

this is a multi-center, double blind, randomized, placebo-controlled, parallel-group, phase 3 study. subjects will be randomly assigned to one of the three treatment groups (dwp14012 a mg or dwp14012 b mg or placebo).

Eligibility criteria:
inclusion criteria: 1. subjects aged between 20 and 75 years 2. subjects who were not observed mucosal break according to the la classification(la grade) on the egd 3. subjects who had experienced major symptom within 3 months 4. subjects who had experienced major symptom within 7 days before randomization. entry into study also required that patients had experienced at least mild symptoms on at least 2 days/week or at least moderate symptoms on at least 1 day/week 5. subjects who is able to understand and follow the instructions 6. subjects who voluntarily signed written informed consent form exclusion criteria: 1. subjects who have barrett's esophagus, gastroesophageal varices, esophageal stenosis, ulcer stenosis, active gastric ulcer, gastrointestinal bleeding or malignant tumor confirmed by endoscopy 2. subjects who have erosive esophagitis, acute upper gastrointestinal bleeding, gastric ulcers or duodenal ulcers within 2 months before visit 1 3. subjects diagnosed with functional dyspepsia, primary esophageal motility disorder, ibs, ibd in the last 3 months 4. subjects who have a history of gastric acid suppression surgery or gastroesophageal surgery 5. subjects with zollinger-ellison syndrome 6. subjects with eosinophilic esophagitis 7. subjects with clinically significant liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease .
the effectiveness of oral health promotion on pneumonia complicating stroke

Conditions: Stroke; Pneumonia; Oral Hygiene

Summary: to investigate the evidence for the integration of oral health promotion as part of interdisciplinary stroke rehabilitation.

pneumonia complicating stroke is very difficult to manage and has a very poor prognosis, leading to a significantly higher risk of death. oral opportunistic pathogens have been reported to be associated with the incidence of pneumonia among non-stroke immunocompromised subjects. preliminary studies found that patients with stroke had higher carriage rates of oral opportunistic pathogens than healthy subjects. therefore, investigators hypothesize that pneumonia complicating stroke is associated with oral opportunistic pathogens, and oral health promotion interventions may reduce the incidence of pneumonia complicating stroke via its effects on the species and relative abundance of oral opportunistic pathogens. in order to prove this, investigators need to (1) firstly conduct a randomized controlled trial to confirm whether oral health promotion is able to reduce the levels of plaque, and the incidence of pneumonia complicating stroke at clinical level; (2) secondly employ metagenomics analysis to compare oral rinse samples and respiratory samples, and to identify pneumonia-associated "oral opportunistic pathogens group"; (3) finally elucidate how oral health promotion influences the species and relative abundance of oral opportunistic pathogens. this proposed study will provide evidence for the integration of oral health promotion as part of interdisciplinary stroke rehabilitation.

Eligibility criteria:
inclusion criteria: * having onset of stroke within 3 days and free of any post-stroke complication * having moderate to severe functional disability- barthel index (bi) scores of \<70 * being conscious and respiring voluntarily without ventilator * not having any lung disease and lower respiratory infection * not have an indwelling naso-gastric feeding tubes * having dysphagia as showed by guss test (the gugging swallowing screen, guss) * having normal cognitive ability or mild impairment- mini mental state examination (mmse) \>18 * having ability to follow instruction (as an assessment of compliance of oral health intervention) * not having systemic administration of antibiotics * not being edentulous exclusion criteria: * mild disability (barthel index \> 70) * having normal swallowing function * edentulous * having an indwelling naso-gastric feeding tubes * having communication disorders, unable to cooperate with family caregivers for oral health promotion

Keywords: oral opportunistic pathogens oral health promotion pneumonia complicating stroke metagenome
retrospective observational study of posterior keratometry measured

Conditions: Keratoconus

Summary: keratoconus is a progressive bilateral disease leading to an apical stromal thinning and an irregular astigmatism by a steepening of the cornea, causing visual impairment. the causes are not yet well known, but it seems to be linked to several comorbidities. keratoconus is a rare and for a long-time asymptomatic condition and its diagnosis needs meticulous screening for the early stages. detecting it as soon as possible is a goal as it could lead to earlier avoiding of contributing factors such as eye rubbing and earlier treatment if needed. the gold standard for keratoconus screening and staging is computerized videotography. it gives information about anterior and posterior corneal bulging, steepening, and thinning. it can be completed by anterior segment optical coherence tomography, which can show corneal scarring. since recently, some biometry devices can give some information about the posterior corneal keratometry trough swept source optical coherence tomography measures. the measurement of the total corneal power instead of an extrapolation lead to better precision in refractive results after cataract surgery in some cases. it also helped to increase our knowledge about posterior corneal astigmatism. in normal eyes, average posterior corneal astigmatism is 0.37 diopters and against the rule in 91 percent of eyes. there is a correlation between the magnitude of anterior and posterior astigmatism. in keratoconus eyes, several studies have shown that there is an alignment between axes of the anterior and posterior corneal astigmatism. these studies have been performed on computerized videotopography devices. the goal of this study was to confirm or deny previous observations about posterior astigmatism in keratoconus eyes, and to assess if the rotation of axis between anterior and posterior astigmatism measured by iol master 700® can be a good sign for detection of early stages and fruste keratoconus.


Eligibility criteria:
inclusion criteria: - keratoconus diagnosed on videotopography exclusion criteria: - loss of sight due to another condition than keratoconus, corneal scarring leading to lack or mistaken data, corneal graft, non-keratoconus related corneal ectasia such as post laser in situ keratomileusis (lasik) ectasia or keratoglobus

Keywords: ophthalmology keratoconus
a study to assess the safety and tolerability of gsk189075 when given with a total daily dose of >/ 2000mg of metformin

Conditions: Diabetes Mellitus, Type 2

Summary: this study will assess safety and tolerability of metformin plus gsk189075 in people with type 2 diabetes. about 48 people will participate in this study. volunteers will not know if they are receiving gsk189075 or a placebo. participation will last about 5 weeks including a run-in period of up to 2 weeks if necessary to increase metformin up to 2000mg daily, a 13-day treatment period, and a follow-up visit about 1 week after the treatment period. volunteers will remain in the research clinic beginning 2 days before they receive the first dose of gsk189075 until after the morning dose on the fourth day and from the afternoon of the 12th day of dosing until the morning after the last dose. they will have clinic visits on dosing days 6, 8, and 10. volunteers will be given equipment and instructions for measuring their blood sugar at home and will be asked to keep a study diary. blood pressure, heart rate, laboratory tests on blood and urine, physical examinations, reports of drug side effects and ecgs will be obtained during the clinic visits to assess safety.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes for at least three months prior to study * diabetes treated with metformin only * give consent and sign an informed consent form. * agree to follow specific requirements of birth control during participation. exclusion criteria: * type i diabetes. * treatment with insulin within 3 months prior to screening * history of diabetic ketoacidosis or lactic acidosis * allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use * excessive blood donation 56 days before the start of the study * urinary tract or bladder infections within four weeks of study start * alcohol abuse or illicit drug use within 12 months of study start * receiving other investigational drugs or participating in other research trials within 30 of the study start * use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start * live alone without regular, daily interactions with someone who can be an emergency contact

Keywords: tolerability gsk189075, metformin, safety, diabetes,
establishment of regional severe trauma management system

Conditions: Trauma; Multiple Trauma; Emergencies

Summary: to evaluate the effects of trauma treatment team establishment on the treatment of patients with severe trauma.

this is a national multi-center, cluster-randomized controlled trial. this cluster-randomized controlled trial will be performed, with counties as the randomization units. the included counties will be randomized into an experimental group and a control group. a trauma treatment team will be only established in the experimental group. the in-hospital mortality rate will be compared between the experimental and control groups to investigate the effects of trauma treatment team establishment on the treatment of patients with severe trauma.

Eligibility criteria:
in this study, three-level subjects (counties, hospitals, and trauma patients) will be included according to the following inclusion and exclusion criteria: * inclusion: * inclusion criteria of counties: * national counties and county-level administrative regions; * local government and health management department have the desire and requirements to establish a standardized trauma emergency treatment system; * more than 500,000 people; * with pre-hospital emergency treatment system; * trauma first aid needs: no less than 20 patients with severe trauma (iss ≥ 16) throughout the county; * inclusion criteria of hospitals: * with the most advanced regional treatment resources during the entire period from trauma recovery to rehabilitation for third-grade class a hospitals; * with basic trauma treatment resources for second-grade class a hospitals; * trauma doctors are on call 24 hours a day and can participate in the early treatment of patients with trauma; * inclusion criteria of patients: * patients with acute trauma occurring within 48 hours; * patients are transferred to trauma treatment center hospital or trauma treatment non-center hospitals; * patients themselves go to or are transferred by their family members to the trauma treatment center hospital or trauma treatment non-center hospita; * exclusion: * exclusion criteria of counties: ○ all second-grade class a or third-grade class a hospitals in the county cannot establish a trauma treatment team because of various reasons; * exclusion criteria of hospitals: ○ hospitals can not establish a trauma treatment team because of various reasons; * exclusion criteria of patients: * patients with trauma from regions not included in this study.

Keywords: severe trauma multiple trauma regional trauma management system trauma management team
mindful breathing awareness through pursed-lip breathing training

Conditions: Chronic Obstructive Pulmonary Disease

Summary: to establish the feasibility of a tool that monitors and motivates people with copd to complete training in mindful pursed-lip breathing to enhance pulmonary rehabilitation at home.

for this pilot study patients who meet the conventional criteria for pulmonary rehabilitation at their clinical appointments will be recruited and scheduled to return for the study. after completing the informed consent, patients will be taught how to don and doff the pulse oximeter, the source of the heart rate and oxygen signals. patients will participate in a demonstration on how to perform the intervention. recruitment will continue until five patients have completed the pilot in a clinic setting. if necessary, the prototype will be modified and testing resumed. once the prototype system has met the criteria for success in the clinic, five of patients will be asked to use the prototype at the clinic and to take it home for a week and perform the intervention at least five times.

Eligibility criteria:
inclusion criteria: * patients must be ≥40 years old * have a diagnosis of gold stage ii, iii, or iv copd documented by pulmonary function testing * have clinically significant breathlessness (breathless when walking on the level or walking a mild hill) * be a current or previous smoker with at least 10 pack-years of cigarette smoking * be hospitalized for an exacerbation of copd. exclusion criteria: * patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency), are planning to move out of the state, are not living in the healthcare area. * patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).
study of zggs18 in combination with zg005 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of zggs18 and zg005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.


Eligibility criteria:
inclusion criteria: * fully understand this study and voluntarily sign the icf. * age 18-75 years, no gender restriction. * patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology. exclusion criteria: * medical history, ct scan, or mri indicates the presence of cns metastases. * other malignancies within 5 years. * any other reason deeming the participant unsuitable for the study, as judged by the investigator.
survival and cardiovascular events in patients with acute myocardial infarction

Conditions: Acute Myocardial Infarction; Coronary Artery Disease

Summary: this prospective and prospective cohort study aims to establish a long-term follow-up cohort of patients with acute myocardial infarction, and combine multi-omics studies, wearable devices, artificial intelligence technology, etc., to describe the clinical characteristics of patients with acute myocardial infarction and the changing trend of treatment strategies, and analyze the related influencing factors. explore new biomarkers and indicators affecting recurrent cardiovascular events for accurate risk stratification and risk prediction; to evaluate the factors affecting lifestyle intervention, drug efficacy and safety, and their impact on outcome, and improve chronic disease management mode, in order to improve the quality of life and prognosis of patients.


Eligibility criteria:
inclusion criteria: * acute myocardial infarction is diagnosed meets the universal definition of acute myocardial infarction exclusion criteria: * did not agree to participate in the study

Keywords: acute myocardial infarction coronary artery disease cohort study
follicular steroid genesis in controlled ovarian stimulation

Conditions: Infertility; Controlled Ovarian Hyperstimulation

Summary: serum concentrations of the different hormones involved in follicular steroid genesis during a cycle of controlled ovarian stimulation with recombinant fsh or hmg will be compared in this study. serum progesterone (p) levels at the end of controlled ovarian stimulation (i.e. the day of triggering) have been related to cycle outcome, in terms of ongoing pregnancy and live birth rates. large cohort studies show that p levels above a certain threshold are associated with poorer cycle outcome. the mechanisms behind p elevation are not well understood yet. it has been shown that p levels are positively related to ovarian response and to the dose of fsh given during cos. furthermore, it has been well documented that p levels at the end of stimulation are significantly higher when recombinant (r) fsh is used for cos when compared to hmg, either in a gnrh agonist long protocol or in a gnrh antagonist protocol. some authors suggest that this finding is explained by the fact that cos with rfsh provides a higher oocyte yield than when hmg is given, so the higher p levels observed would be explained by the larger number of follicles developed when rfsh is used. on the other hand, other authors explain this event by a different follicular esteroidogenesis when hmg is used for cos compared to rfsh the hypotheisis behind this assumption is that rfsh enhances p synthesis from its precursor pregnenolone in the granulosa cells. this p is unable to be further metabolized into androgens because of the lack of 17-20 lyase in the human granulosa cells, and therefore is delivered into circulation. on the other hand, when hmg is given for cos, the ∆4 pathway is promoted, and pregnenolone will be catabolized in to dehidroepiandrostenodione (dhea), in the theca cells, and this one to androstenodione, which will be finally aromatized in to estrogens. this mechanism will explain the lower p and higher e2 levels observed in hmg cycles in comparison to rfsh cycles.


Eligibility criteria:
inclusion criteria: * good physical and psychological condition * normal menstrual cycle (25-35 days) * normal ovarian reserve defined by serum anh010-30 pmol/l * all other criteria to fulfill by oocyte donors exclusion criteria: * kidney failure * ovarian polyquistic syndrome * any systemic or metabolic disfunction that counter indicates the use of gonadotrophins * any other reason that involves exclusion of the oocyte donation program